Stay updated on Psilocybin-Induced Neuroplasticity in MDD Clinical Trial
Sign up to get notified when there's something new on the Psilocybin-Induced Neuroplasticity in MDD Clinical Trial page.

Latest updates to the Psilocybin-Induced Neuroplasticity in MDD Clinical Trial page
- CheckyesterdayChange DetectedThe record for Yale University’s psilocybin study in major depressive disorder is available again, with details on its design, eligibility criteria, interventions, outcome measures, locations, and study status. The prior access-denied message and Home link are removed.SummaryDifference46%

- Check8 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check14 days agoChange DetectedA notice was added about NIH website terminology changes, stating that some content may use “Super Intelligence” instead of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check21 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check28 days agoChange DetectedThe site revision label in the footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check49 days agoChange DetectedThe study page is now displaying a 403 Forbidden error instead of the prior content, replacing the study details with an access-denied page. This suggests restricted access or a site misconfiguration that hides the original page content and navigation.SummaryDifference18%

Stay in the know with updates to Psilocybin-Induced Neuroplasticity in MDD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Psilocybin-Induced Neuroplasticity in MDD Clinical Trial page.